Compare CELZ & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELZ | PMCB |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.3M |
| IPO Year | 2008 | 2001 |
| Metric | CELZ | PMCB |
|---|---|---|
| Price | $0.96 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 599.3K | 87.9K |
| Earning Date | 05-08-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.62 | $0.47 |
| 52 Week High | $6.25 | $1.51 |
| Indicator | CELZ | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 24.65 |
| Support Level | $0.80 | N/A |
| Resistance Level | $1.97 | $0.57 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 4.01 | 9.16 |
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.